Crossmark

Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity

Published Online: 2022-12-30

Published Print: 2022-12

Authors

Campagna, Maria Pia

Xavier, Alexandre

Lea, Rodney A.

Stankovich, Jim

Maltby, Vicki E.

Butzkueven, Helmut

Lechner-Scott, Jeannette

Scott, Rodney J.

Jokubaitis, Vilija G.
Funding

Funding for this research was provided by:

Multiple Sclerosis Research Australia (18-0424, 18-0424, 18-0424, 18-0424, 18-0424, 18-0424)

Royal Melbourne Hospital Home Lottery Grant (MH2013-055, MH2013-055)

Pennycook Foundation Grant

MSBase Foundation Project Grant

Charity Works for MS Project Grant

Monash University Project Grant
License Information

Text and Data Mining valid from 2022-12-01

Version of Record valid from 2022-12-30
More Information

Article History

Received: 8 August 2022

Accepted: 2 December 2022

First Online: 30 December 2022

Declarations

:

: Ethics approval for the collection of demographic, clinical and treatment data via the MSBase Registry was obtained from the Alfred Health Human Research Ethics Committee (528/12) and from institutional review boards at all participating centres. The Australian National Mutual Acceptance Scheme approved the genetic component of this study (HREC/13/MH/189). Written informed consent was obtained from participants at each site as per local laws.

: Participants signed informed consent regarding publishing their data.

: The authors report no competing interests.

Document is current